Surgery for Small Bowel Crohn’s Disease

  • Paul Rooney
  • Nicola Eardley


Surgery cannot “cure” Crohn’s disease but should be about best managing the complications of the disease. It is the transmural inflammation that is typical of Crohn’s disease which gives rise to the complications of stricture, abscess, and fistulation. Symptoms may include abdominal pain, diarrhea, malaise, fever, anorexia, weight loss, or anemia and will vary depending upon the underlying nature and distribution of the disease. In an individual patient, the disease tends to be either stricturing or fistulating, and recurrent disease after surgical resection tends to recur in a similar pattern [1]. Crohn’s disease most commonly affects the terminal ileum (when it was first reported, it was termed “terminal ileitis” [2]) with ileocolic disease present in approximately 40% of patients, ileal disease in 30%, and colonic/anal disease in less than 30% [3].


Intestinal Fistula Anastomotic Failure Ileocolic Anastomosis Terminal Ileitis Fibrotic Stricture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Greenstein AJ, Lachman P, Sachar DB, et al. Perforating and non-perforating indications for repeated operations in Crohn’s disease: evidence for two clinical forms. Gut. 1988;29:588–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Crohn BB, Ginzburg L, Oppenheimer GD. Regional ileitis: a pathological and clinical entity. JAMA. 1932;99:1323–9.CrossRefGoogle Scholar
  3. 3.
    Farmer RG, Hawk WA, Turnbull RB. Clinical patterns in Crohn’s disease: a statistical study of 615 cases. Gastroenterology. 1975;68:627–35.PubMedGoogle Scholar
  4. 4.
    Truelove SC, Pena AS. Course and prognosis of Crohn’s disease. Gut. 1976;17:192–201.PubMedCrossRefGoogle Scholar
  5. 5.
    Carter MJ, Lobo AJ, Travis SPL, IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2004;53 Suppl 5:v1–16.PubMedCrossRefGoogle Scholar
  6. 6.
    Habauer SB, Stromberg U. Oral Pentasa in the treatment of active Crohn’s disease: a meta-analysis of double-blind, placebo-controlled trials. Clin Gastroenterol Hepatol. 2004;2:379–88.CrossRefGoogle Scholar
  7. 7.
    Akobeng AK, Gardener E. Oral 5-aminosalicylic acid in maintenance of medically-induced remission in Crohn’s disease. Cochrane Database Syst Rev. 2005;(1):CD003715.pub2. DOI: 10.1002/14651858.Google Scholar
  8. 8.
    Camma C, Giunta M, Rosselli M, et al. Mesalamine in the maintenance treatment of Crohn’s disease: a meta-analysis adjusted for confounding variables. Gastroenterology. 1997;113:1465–73.PubMedCrossRefGoogle Scholar
  9. 9.
    Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse of Crohn’s disease with mesalamine: European Cooperative Crohn’s Disease Study VI. Gastroenterology. 2000;118:264–73.PubMedCrossRefGoogle Scholar
  10. 10.
    Caprilli R, Gassull MA, Escher JC, et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. 2006;55 Suppl 1:i36–58.PubMedCrossRefGoogle Scholar
  11. 11.
    Yamamoto T, Allan RN, Keighley MR. Risk factors for intra-abdominal sepsis after surgery in Crohn’s disease. Dis Colon Rectum. 2000;43(8):1141–5.PubMedCrossRefGoogle Scholar
  12. 12.
    Griffiths AM, Ohlsson A, Sherman PM, Sutherland LR. Meta-analysis of enteral nutrition as a primary treatment of active Crohn’s disease. Gastroenterology. 1995;108:1056–67.PubMedCrossRefGoogle Scholar
  13. 13.
    Fernandez-Banares F, Cabre E, Esteve-Comas M, Gassull MA. How effective is enteral nutrition in inducing clinical remission in active Crohn’s disease? A meta-analysis of randomized clinical trials. JPEN J Parenter Enteral Nutr. 1995;19:356–64.PubMedCrossRefGoogle Scholar
  14. 14.
    Messori A, Trallori G, D’Albasio G, et al. Defined-formula diets versus steroids in the treatment of active Crohn’s disease: a meta-analysis. Scand J Gastroenterol. 1996;31:267–72.PubMedCrossRefGoogle Scholar
  15. 15.
    Zachos M, Tondeur M, Griffiths AM. Enteral nutritional therapy for inducing remission in Crohn’s disease. Cochrane Database Syst Rev. 2001;3:CD000542.PubMedGoogle Scholar
  16. 16.
    Bouhnik Y, Lemann M, Mary JY, et al. Long term follow-up of patients with Crohn’s disease treated with azathioprine or 6-mercaptopurine. Lancet. 1996;347:215–9.PubMedCrossRefGoogle Scholar
  17. 17.
    Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn’s disease. Cochrane Database Syst Rev. 2009;4:CD006873.PubMedGoogle Scholar
  18. 18.
    Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.PubMedCrossRefGoogle Scholar
  19. 19.
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med. 1995;332:292–7.PubMedCrossRefGoogle Scholar
  20. 20.
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med. 2000;342:1664–6.CrossRefGoogle Scholar
  21. 21.
    Connell W, Miller A. Treating inflammatory bowel disease during pregnancy: risks and safety of drug therapy. Drug Saf. 1999;21:311–23.PubMedCrossRefGoogle Scholar
  22. 22.
    Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 1995;108:1617–21.PubMedCrossRefGoogle Scholar
  23. 23.
    Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of post operative Crohn’s disease recurrence: a randomized, double blind, placebo controlled trial. Gastroenterology. 2005;128(4):856–61.PubMedCrossRefGoogle Scholar
  24. 24.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomized trial. Lancet. 2002;359:1541–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Rutgeerts P, Feagan BG, Lichtenstein GR, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. 2004;126:402–13.PubMedCrossRefGoogle Scholar
  26. 26.
    Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med. 2004;350:876–85.PubMedCrossRefGoogle Scholar
  27. 27.
    Hanauer SB, Sandborn WJ, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC I trial. Gastroenterology. 2006;130:323–33.PubMedCrossRefGoogle Scholar
  28. 28.
    Sandborn WJ, Hanauer SB, Rutgeerts P, et al. Adalimumab for maintenance treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 2007;56:1232–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Hommes D, Baert F, Van Assche G, et al. A randomized controlled trial evaluating the ideal medical management for Crohn’s disease: top-down verses step-up strategies. Gastroenterology. 2005;128 Suppl 2:A577.Google Scholar
  30. 30.
    Calkins BM. A meta-analysis of the role of smoking in inflammatory bowel disease. Dig Dis Sci. 1989;34:1841–54.PubMedCrossRefGoogle Scholar
  31. 31.
    Timmer A, Sutherland LR, Martin F. Oral contraceptive use and smoking are risk factors for relapse in Crohn’s disease. Canadian Mesalamine for Remission of Crohn’s Disease Study Group. Gastroenterology. 1998;114:1143–50.PubMedCrossRefGoogle Scholar
  32. 32.
    Cottone M, Rosselli M, Orlando A, et al. Smoking habits and recurrence in Crohn’s disease. Gastroenterology. 1994;106:643–8.PubMedGoogle Scholar
  33. 33.
    Cosnes J, Beaugerie L, Carbonnel F, et al. Smoking cessation and the course of Crohn’s disease: an intervention study. Gastroenterology. 2001;120:1093–9.PubMedCrossRefGoogle Scholar
  34. 34.
    Michelassi F, Stella M, Balestracci T, et al. Incidence, diagnosis and treatment of enteric and colorectal fistulae in patients with Crohn’s disease. Ann Surg. 1993;218(5):660–6.PubMedCrossRefGoogle Scholar
  35. 35.
    Poritz LS, Rowe WA, Koltun WA. Remicade does not abolish the need for surgery in fistulizing Crohn’s disease. Dis Colon Rectum. 2002;45(46):771–5.PubMedCrossRefGoogle Scholar
  36. 36.
    Kaushal M, Carlson GL. Management of enterocutaneous fistulas. Clin Colon Rectal Surg. 2004;17(2):79–88.PubMedCrossRefGoogle Scholar
  37. 37.
    D’Haens G, van Deventer S, van Hogzand R, et al. Endoscopic and histological healing with infliximab anti-tumour necrosis factor antibodies in Crohn’s disease: European multi-centre trial. Gastroenterology. 1999;166:1029–34.CrossRefGoogle Scholar
  38. 38.
    Targan SR, Hanauer SB, van Deventer SJ, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn’s disease. Crohn’s Disease cA2 Study Group. N Engl J Med. 1997;337(15):1029–35.PubMedCrossRefGoogle Scholar
  39. 39.
    Appau KA, Fazio VW, Shen B, et al. Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn’s patients. J Gastrointest Surg. 2008;12(10):1738–44.PubMedCrossRefGoogle Scholar
  40. 40.
    Kunitake H, Hodin R, Shellito PC, et al. Perioperative treatment with infliximab in patients with Crohn’s disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg. 2008;12(10):1730–6.PubMedCrossRefGoogle Scholar
  41. 41.
    Sewell JL, Mahadevan U. Infliximab and surgical complications: truth or perception? Gastroenterology. 2009;136(1):354–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Hulten L. Surgical treatment of Crohn’s disease of the small bowel or ileocecum. World J Surg. 1988;12:180–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Scott NA, Hughes LE. Timing of ileocolonic resection for symptomatic Crohn’s disease-the patient’s view. Gut. 1994;35:656–7.PubMedCrossRefGoogle Scholar
  44. 44.
    Burnstein CN, Balnchard JF, Houston DS, et al. The incidence of deep venous thrombosis and pulmonary embolism among patients with inflammatory bowel disease: a population-based cohort study. Thromb Haemost. 2001;85(3):430–4.Google Scholar
  45. 45.
    Nicholson G, Burrin JM, Hall GM. Peri-operative steroid supplementation. Anaesthesia. 1998;53:1091–104.PubMedCrossRefGoogle Scholar
  46. 46.
    Rosenthal RJ, Bashankaev B, Wexner SD. Laparoscopic management of inflammatory bowel disease. Dig Dis. 2009;27(4):560–4.PubMedCrossRefGoogle Scholar
  47. 47.
    Fazio VW, Marchetti F, Church M, et al. Effect of resection margins on the recurrence of Crohn’s disease in the small bowel: a randomized controlled trial. Ann Surg. 1996;224:563–71.PubMedCrossRefGoogle Scholar
  48. 48.
    Greenstein AJ, Sachar D, Pucillo A, et al. Cancer in Crohn’s disease after diversionary surgery. A report of seven carcinomas occurring in excluded bowel. Am J Surg. 1978;135(1):86–90.PubMedCrossRefGoogle Scholar
  49. 49.
    Yamamoto T, Fazio VW, Tekkis PP. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis Colon Rectum. 2007;50(11):1968–86.PubMedCrossRefGoogle Scholar
  50. 50.
    Choy PY, Bissett IP, Docherty JG, et al. Stapled versus handsewn methods for ileocolic anastomoses. Cochrane Database Syst Rev. 2007;3:CD004320.PubMedGoogle Scholar
  51. 51.
    Resegotti A, Astegiano M, Farina EC, et al. Side-to-side stapled anastomosis strongly reduces anastamotic leak rates in Crohn’s disease surgery. Dis Colon Rectum. 2005;48(3):464–8.PubMedCrossRefGoogle Scholar
  52. 52.
    McLeod RS, Wolff BG, Ross S, et al. Recurrence of Crohn’s disease after ileocolic resection is not affected by anastamotic type: results of a multicenter, randomized, controlled trial. Dis Colon Rectum. 2009;52(5):919–27.PubMedCrossRefGoogle Scholar
  53. 53.
    Weston LA, Roberts PL, Schoetz DJ, et al. Ileocolic resection for acute presentation of Crohn’s disease of the ileum. Dis Colon Rectum. 1996;39:841–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Olaison G, Smedh K, Sjodahl R. Natural course of Crohn’s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut. 1992;33:331–5.PubMedCrossRefGoogle Scholar
  55. 55.
    Bemelman WA, Ivenski M, van Hogezand RA, et al. How effective is extensive nonsurgical treatment of patients with clinically active Crohn’s disease of the terminal ileum in preventing surgery? Dig Surg. 2001;18:56–60.PubMedCrossRefGoogle Scholar
  56. 56.
    Platell C, Mackay J, Woods R. A multivariate analysis of risk factors associated with recurrence following surgery for Crohn’s disease. Colorectal Dis. 2001;3:100–6.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London Limited 2012

Authors and Affiliations

  1. 1.Department of SurgeryRoyal Liverpool University HospitalLiverpoolUK

Personalised recommendations